44,901 Shares in Illumina, Inc. (ILMN) Acquired by Old Mutual Global Investors UK Ltd.

Old Mutual Global Investors UK Ltd. purchased a new position in Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 44,901 shares of the life sciences company’s stock, valued at approximately $9,810,000.

Other institutional investors also recently bought and sold shares of the company. SeaCrest Wealth Management LLC purchased a new stake in shares of Illumina in the 4th quarter worth approximately $154,000. Dupont Capital Management Corp purchased a new stake in shares of Illumina in the 3rd quarter worth approximately $153,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its stake in shares of Illumina by 113.9% in the 4th quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 770 shares of the life sciences company’s stock worth $168,000 after buying an additional 410 shares during the last quarter. Advisory Services Network LLC grew its stake in shares of Illumina by 13.0% in the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after buying an additional 89 shares during the last quarter. Finally, Riverbridge Partners LLC purchased a new stake in shares of Illumina in the 4th quarter worth approximately $202,000. Institutional investors own 92.04% of the company’s stock.

Several brokerages have commented on ILMN. Citigroup upgraded Illumina from a “neutral” rating to a “buy” rating and increased their target price for the company from $260.00 to $275.00 in a research note on Monday, February 5th. BidaskClub downgraded Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, February 3rd. Barclays increased their target price on Illumina from $200.00 to $215.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 31st. Morgan Stanley increased their target price on Illumina from $145.00 to $157.00 and gave the company an “underweight” rating in a research note on Wednesday, January 31st. Finally, Leerink Swann increased their target price on Illumina from $250.00 to $276.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $241.39.

In other news, Director Robert S. Epstein sold 1,250 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $226.55, for a total value of $283,187.50. Following the transaction, the director now directly owns 9,088 shares in the company, valued at approximately $2,058,886.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Marc Stapley sold 2,000 shares of the firm’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $216.87, for a total value of $433,740.00. Following the completion of the transaction, the executive vice president now owns 27,952 shares in the company, valued at $6,061,950.24. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 114,440 shares of company stock worth $25,318,904. Company insiders own 0.89% of the company’s stock.

Illumina, Inc. (NASDAQ:ILMN) opened at $223.11 on Thursday. The stock has a market capitalization of $32,404.68, a price-to-earnings ratio of 54.97, a PEG ratio of 2.91 and a beta of 0.92. Illumina, Inc. has a 52 week low of $158.02 and a 52 week high of $248.97. The company has a quick ratio of 3.55, a current ratio of 3.99 and a debt-to-equity ratio of 0.42.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.22. The firm had revenue of $778.00 million for the quarter, compared to the consensus estimate of $752.04 million. Illumina had a return on equity of 21.52% and a net margin of 26.56%. The company’s revenue for the quarter was up 25.7% on a year-over-year basis. During the same period last year, the business posted $0.85 EPS. research analysts predict that Illumina, Inc. will post 4.59 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Week Herald and is the property of of Week Herald. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://weekherald.com/2018/02/15/44901-shares-in-illumina-inc-ilmn-acquired-by-old-mutual-global-investors-uk-ltd.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply